Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory-Reference-Cited by-同舟云学术

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

Published:2023-05 Issue: Volume:91 Page:104562
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

McLean Chelsea,Barry Houreratou^ORCID,Kieh Mark,Anywaine Zacchaeus,Tapima Rogers Baimba,Doumbia Seydou,Sirima Sodiomon B.,Serry-Bangura Alimamy,Habib Beavogui Abdoul,Gaddah Auguste,Katwere Michael,Hendriks Jenny,Keshinro Babajide,Eholie Serge,Kibuuka Hannah,Kennedy Stephen B.,Anzala Omu,Samai Mohamed,D'Ortenzio Eric,Leigh Bailah,Sow Samba,Thiébaut Rodolphe,Greenwood Brian,Watson-Jones Deborah,Douoguih Macaya,Luhn Kerstin,Robinson Cynthia

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference21 articles.

1. Ebola virus disease distribution map: cases of Ebola virus disease in Africa since,1976

2. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate;Roozendaal;NPJ Vaccines,2020

3. Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples;Rudge;PLoS One,2019

4. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa;Barry;PLoS Med,2021

5. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial;Anywaine;PLoS Med,2022